Report · S7646
Ovarian Cancer Research Program — Teal Innovator for OCRP 2011: A Researcher’s Perspective, Garry Nolan
The public Defense programme booklet identifies Nolan as the OCRP2011 Teal Innovator. His perspective reports ovarian-cancer cohort classification and describes hoped-for clinical benefits. This documents a public biomedical programme association; it establishes no classified UAP approach or access.
Read the document at cdmrp.health.milWhat we checked
Read complete printed10 Nolan narrative/byline485–563 in the web PDF rendition, plus cover, award mechanism and generic review process. Other23 booklet leaves and clinical sidebar excluded. OCRP2011 heading differs from2012 filename/FY12 context; exact publication and award-execution dates unknown.
Selected Nolan perspective and programme context read
How we check sources
Not checked yet
- Native screenshot failed and ordinary download failed certificate verification before receipt; routes closed. No original PDF/hash/native pixels, underlying data, cited Science paper, contracts or FDA records reviewed.
- Author-reported40-sample findings and future validation/benefit hopes are not replicated clinical outcomes. Public support is not a private UAP invitation, classified access or material custody. No whole-booklet, additional journal main-text or book completion credit.
Cite this record
Garry Nolan, Congressionally Directed Medical Research Programs. Ovarian Cancer Research Program — Teal Innovator for OCRP 2011: A Researcher’s Perspective, Garry Nolan. BioParity S7646. https://bioparity.io/sources/S7646Record data (JSON)